CRS and ICANS
| . | All, n (%) . | Axi-cel, n (%) . | Tisa-cel, n (%) . | P . |
|---|---|---|---|---|
| CRS 1-4 | 259 (73) | 141 (81) | 118 (65) | .003 |
| CRS ≥3 | 42 (12) | 18 (10) | 24 (13) | n.s. |
| CRS 5 | 1 (0.3) | 0 | 1 (0.5) | — |
| ICANS 1-4 | 116 (33) | 76 (44) | 40 (22) | <.0001 |
| ICANS ≥3 | 40 (11) | 28 (16) | 12 (7) | .004 |
| ICANS 5 | 1 (0.3) | 1 (0.6) | 0 | — |
| . | All, n (%) . | Axi-cel, n (%) . | Tisa-cel, n (%) . | P . |
|---|---|---|---|---|
| CRS 1-4 | 259 (73) | 141 (81) | 118 (65) | .003 |
| CRS ≥3 | 42 (12) | 18 (10) | 24 (13) | n.s. |
| CRS 5 | 1 (0.3) | 0 | 1 (0.5) | — |
| ICANS 1-4 | 116 (33) | 76 (44) | 40 (22) | <.0001 |
| ICANS ≥3 | 40 (11) | 28 (16) | 12 (7) | .004 |
| ICANS 5 | 1 (0.3) | 1 (0.6) | 0 | — |
P value compared with no toxicity.